JP2003506056A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003506056A5 JP2003506056A5 JP2001514749A JP2001514749A JP2003506056A5 JP 2003506056 A5 JP2003506056 A5 JP 2003506056A5 JP 2001514749 A JP2001514749 A JP 2001514749A JP 2001514749 A JP2001514749 A JP 2001514749A JP 2003506056 A5 JP2003506056 A5 JP 2003506056A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- biological sample
- patient
- tumor
- anx7
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 description 23
- 239000012472 biological sample Substances 0.000 description 15
- 206010028980 Neoplasm Diseases 0.000 description 9
- 102100034273 Annexin A7 Human genes 0.000 description 8
- 101000780144 Homo sapiens Annexin A7 Proteins 0.000 description 8
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 208000000453 Skin Neoplasms Diseases 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 201000000849 skin cancer Diseases 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 210000003699 striated muscle Anatomy 0.000 description 2
- 206010073360 Appendix cancer Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 101100219041 Caenorhabditis briggsae bre-2.1 gene Proteins 0.000 description 1
- 101100219042 Caenorhabditis elegans bre-2 gene Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 206010023774 Large cell lung cancer Diseases 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 201000004404 Neurofibroma Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 208000021780 appendiceal neoplasm Diseases 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 201000008361 ganglioneuroma Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000016356 hereditary diffuse gastric adenocarcinoma Diseases 0.000 description 1
- 208000018821 hormone-resistant prostate carcinoma Diseases 0.000 description 1
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000009546 lung large cell carcinoma Diseases 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 1
- 208000017708 myomatous neoplasm Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 208000029974 neurofibrosarcoma Diseases 0.000 description 1
- 208000014500 neuronal tumor Diseases 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 208000007312 paraganglioma Diseases 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
Description
【特許請求の範囲】
【請求項1】
患者から取得した生物学的サンプル中の腫瘍を検出する方法であって、該生物学的サンプルのANX7タンパク質発現をアッセイすることを含み、
ANX7タンパク質が該生物学的サンプル中で無視できるレベルを超えて発現されない場合に腫瘍が検出され;さらに
該生物学的サンプルは、前立腺、皮膚、リンパ、神経、膵臓、結腸、食道、胆嚢、又は虫垂から取得され、該腫瘍はそれぞれ前立腺癌、皮膚癌、リンパ腫瘍、神経腫瘍、膵臓癌、結腸癌、食道癌、胆嚢癌、又は虫垂癌である、上記方法。
【請求項2】
生物学的サンプル中のANX7タンパク質発現をアッセイすることが、該生物学的サンプル中のANX7タンパク質に特異的に結合することができる少なくとも1つの抗体を導入することを含む、請求項1に記載の方法。
【請求項3】
少なくとも1つの抗体がモノクローナル抗体である、請求項2に記載の方法。
【請求項4】
モノクローナル抗体が標識されている、請求項3に記載の方法。
【請求項5】
患者が前立腺癌に罹患している、請求項1に記載の方法。
【請求項6】
前立腺癌が、転移性前立腺癌及び局所再発性のホルモン抵抗性前立腺癌のうち1以上から選択される、請求項5に記載の方法。
【請求項7】
患者から取得した生物学的サンプル中の増殖細胞の割合をアッセイすることをさらに含む、請求項3に記載の方法。
【請求項8】
患者から取得した生物学的サンプル中の増殖細胞の割合をアッセイすることが、Ki67抗体を該生物学的サンプルへ導入することを含む、請求項7に記載の方法。
【請求項9】
患者が黒色腫、転移扁平上皮細胞皮膚癌、皮膚基底細胞癌、及び扁平上皮細胞皮膚癌のうち1以上に罹患している、請求項1に記載の方法。
【請求項10】
患者が慢性骨髄球性白血病、ホジキンリンパ腫、及び非ホジキンリンパ腫のうち1以上に罹患している、請求項1に記載の方法。
【請求項11】
患者が節神経腫、悪性神経鞘腫、髄膜腫、神経線維腫、傍神経節腫、及び神経鞘腫のうち1以上に罹患している、請求項1に記載の方法。
【請求項12】
患者から取得した生物学的サンプル中の腫瘍を検出する方法であって、該生物学的サンプルのANX7タンパク質発現をアッセイすることを含み、
ANX7タンパク質が該生物学的サンプル中で無視できるレベルを超えて発現される場合に腫瘍が検出され;さらに
該生物学的サンプルは、乳房、横紋筋、精巣、肺、胃、又は小腸から取得され、該腫瘍はそれぞれ乳癌、横紋筋腫瘍、精巣癌、肺癌、胃癌、又は小腸癌である、上記方法。
【請求項13】
患者が乳癌に罹患している、請求項12に記載の方法。
【請求項14】
乳癌が転移侵襲性乳管癌、転移侵襲性小葉型乳癌、及びBRE-2グレードの乳癌のうち1以上から選択される、請求項13に記載の方法。
【請求項15】
患者が線維肉腫、カポジ肉腫、平滑筋肉腫、脂肪肉腫、横紋筋肉腫、及び滑膜肉腫のうち1以上に罹患している、請求項12に記載の方法。
【請求項16】
患者がライディッヒ腫瘍及びセミノーマのうち1以上に罹患している、請求項12に記載の方法。
【請求項17】
患者がカルチノイド肺癌、腺癌、大細胞肺癌、小細胞肺癌、及び扁平上皮細胞肺癌のうち1以上に罹患している、請求項12に記載の方法。
【請求項18】
生物学的サンプル中のANX7タンパク質発現をアッセイすることが、該生物学的サンプル中のANX7タンパク質と特異的に結合することができる少なくとも1つの抗体を導入することを含む、請求項12に記載の方法。
【請求項19】
少なくとも1つの抗体がモノクローナル抗体である、請求項18に記載の方法。
【請求項20】
モノクローナル抗体が標識されている、請求項19に記載の方法。
[Claims]
(1)
A method of detecting a tumor in a biological sample obtained from a patient, comprising assaying ANX7 protein expression of said biological sample,
A tumor is detected if the ANX7 protein is not expressed in the biological sample at more than negligible levels; and the biological sample is a prostate, skin, lymph, nerve, pancreas, colon, esophagus, gallbladder, or The above method, wherein the tumor is obtained from an appendix, and the tumor is a prostate cancer, a skin cancer, a lymph tumor, a neuronal tumor, a pancreatic cancer, a colon cancer, an esophageal cancer, a gallbladder cancer, or an appendix cancer, respectively.
(2)
2. The method of claim 1, wherein assaying ANX7 protein expression in the biological sample comprises introducing at least one antibody capable of specifically binding to ANX7 protein in the biological sample. Method.
(3)
3. The method according to claim 2, wherein the at least one antibody is a monoclonal antibody.
(4)
4. The method of claim 3, wherein the monoclonal antibody is labeled.
(5)
2. The method of claim 1, wherein the patient has prostate cancer.
6.
6. The method of claim 5, wherein the prostate cancer is selected from one or more of metastatic prostate cancer and locally recurrent hormone-resistant prostate cancer.
7.
4. The method of claim 3, further comprising assaying a percentage of proliferating cells in a biological sample obtained from the patient.
Claim 8.
8. The method of claim 7, wherein assaying the percentage of proliferating cells in a biological sample obtained from the patient comprises introducing a Ki67 antibody to the biological sample.
9.
2. The method of claim 1, wherein the patient has one or more of melanoma, metastatic squamous cell skin cancer, basal skin cell carcinoma, and squamous cell skin cancer.
10.
2. The method of claim 1, wherein the patient has one or more of chronic myelocytic leukemia, Hodgkin's lymphoma, and non-Hodgkin's lymphoma.
11.
2. The method of claim 1, wherein the patient has one or more of ganglioneuroma, malignant schwannomas, meningiomas, neurofibromas, paragangliomas, and schwannomas.
12.
A method of detecting a tumor in a biological sample obtained from a patient, comprising assaying ANX7 protein expression of said biological sample,
A tumor is detected when ANX7 protein is expressed in the biological sample at negligible levels; further, the biological sample is obtained from breast, striated muscle, testis, lung, stomach, or small intestine Wherein the tumor is a breast cancer, a striated muscle tumor, a testis cancer, a lung cancer, a gastric cancer, or a small intestine cancer, respectively.
Claim 13
13. The method of claim 12, wherein the patient has breast cancer.
14.
14. The method of claim 13, wherein the breast cancer is selected from one or more of metastatic invasive ductal carcinoma, metastatic invasive lobular breast cancer, and BRE-2 grade breast cancer.
15.
13. The method of claim 12, wherein the patient has one or more of fibrosarcoma, Kaposi's sarcoma, leiomyosarcoma, liposarcoma, rhabdomyosarcoma, and synovial sarcoma.
16.
13. The method of claim 12, wherein the patient has one or more of a Leydig tumor and a seminoma.
17.
13. The method of claim 12, wherein the patient has one or more of carcinoid lung cancer, adenocarcinoma, large cell lung cancer, small cell lung cancer, and squamous cell lung cancer.
18.
13. The method of claim 12, wherein assaying ANX7 protein expression in a biological sample comprises introducing at least one antibody capable of specifically binding to ANX7 protein in the biological sample. Method.
(19)
19. The method according to claim 18, wherein the at least one antibody is a monoclonal antibody.
20.
20. The method of claim 19, wherein the monoclonal antibody is labeled.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14725599P | 1999-08-05 | 1999-08-05 | |
US60/147,255 | 1999-08-05 | ||
PCT/US2000/021409 WO2001010199A1 (en) | 1999-08-05 | 2000-08-07 | A knockout mouse for the tumor suppressor gene anx7 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2003506056A JP2003506056A (en) | 2003-02-18 |
JP2003506056A5 true JP2003506056A5 (en) | 2007-10-04 |
Family
ID=22520863
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2001514749A Withdrawn JP2003506056A (en) | 1999-08-05 | 2000-08-07 | Knockout mouse of tumor suppressor gene anx7 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1211931A4 (en) |
JP (1) | JP2003506056A (en) |
AU (1) | AU779905B2 (en) |
CA (1) | CA2378292A1 (en) |
WO (1) | WO2001010199A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ536548A (en) * | 2002-04-16 | 2007-11-30 | Dana Farber Cancer Inst Inc | Using stem cells to make chimeric non-human animals having tumors or the ability to develop tumors |
EP3045470A1 (en) | 2015-01-15 | 2016-07-20 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | Modulators of the function of the core domain of annexins, and uses thereof in autoimmune and/or cancer therapy |
JP7377604B2 (en) | 2016-06-10 | 2023-11-10 | ドイチェス クレープスフォルシュングスツェントルム シュティフトゥング デス エッフェントリッヒェン レヒツ | Annexin core domain and its use in antigen delivery and vaccination |
-
2000
- 2000-08-07 WO PCT/US2000/021409 patent/WO2001010199A1/en active IP Right Grant
- 2000-08-07 CA CA002378292A patent/CA2378292A1/en not_active Abandoned
- 2000-08-07 EP EP00953846A patent/EP1211931A4/en not_active Withdrawn
- 2000-08-07 AU AU66224/00A patent/AU779905B2/en not_active Ceased
- 2000-08-07 JP JP2001514749A patent/JP2003506056A/en not_active Withdrawn
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Gu et al. | CCL14 is a prognostic biomarker and correlates with immune infiltrates in hepatocellular carcinoma | |
Aurello et al. | Influence of perineural invasion in predicting overall survival and disease-free survival in patients with locally advanced gastric cancer | |
Ishibashi et al. | CD147 and matrix metalloproteinase‐2 protein expression as significant prognostic factors in esophageal squamous cell carcinoma | |
Duan et al. | Clinical significance of the immunostimulatory MHC class I chain-related molecule A and NKG2D receptor on NK cells in pancreatic cancer | |
WO2001062206A3 (en) | N-cadherin modulated migration, invasion, and metastasis | |
Kato et al. | Semaphorin 4D, a lymphocyte semaphorin, enhances tumor cell motility through binding its receptor, plexinB1, in pancreatic cancer | |
Yagi et al. | Prognostic factors in stage IV gastric cancer: univariate and multivariate analyses | |
AU1726199A (en) | Metastatic cancer regulated gene | |
Baumeister et al. | Histological variants in non-muscle invasive bladder cancer | |
WO2004045521A3 (en) | Detection of micro metastasis of melanoma and breast cancer in paraffin-embedded tumor draining lymph nodes by multimaker quantitative rt-pcr | |
Sasahira et al. | Receptor for advanced glycation end products (RAGE) is important in the prediction of recurrence in human oral squamous cell carcinoma | |
Abdelmoez et al. | Screening and identification of molecular targets for cancer therapy | |
Ettel et al. | Expression and prognostic value of NSD1 and SETD2 in pancreatic ductal adenocarcinoma and its precursor lesions | |
Strizova et al. | NK and T cells with a cytotoxic/migratory phenotype accumulate in peritumoral tissue of patients with clear cell renal carcinoma | |
Ahmed Haji Omar et al. | Epithelial and stromal syndecan‐1 and‐2 are distinctly expressed in oral‐and cutaneous squamous cell carcinomas | |
JP2003506056A5 (en) | ||
Cutuli et al. | A French national survey on infiltrating breast cancer: analysis of clinico-pathological features and treatment modalities in 1159 patients | |
Halder et al. | CDX2 expression in gastric carcinoma: A clinicopathological study | |
Lopez | Molecular subtyping bladder cancer: Is it ready for clinical practice? | |
Bhatnagar et al. | Serum-based protein biomarkers for detection of lung cancer | |
Ozğul et al. | Expression of epidermal growth factor receptor in normal colonic mucosa and in adenocarcinomas of the colon. | |
Çoban et al. | The utility of serum receptor-binding cancer antigen expressed on SiSo cells in gastrointestinal tract cancers | |
Theocharis et al. | RCAS1 expression in mobile tongue squamous cell carcinoma: an immunohistochemical study | |
Han et al. | Unclassified mucin phenotype of gastric adenocarcinoma exhibits the highest invasiveness | |
Chen et al. | In silico analysis of the prognostic value of FAS mRNA in malignancies |